Novartis' plans to wrestle Eylea market share take a hit as Beovu is linked to safety concerns
While Regeneron’s flagship eye therapy Eylea hurtles towards a patent cliff, the sales of its main rival — Novartis’ Beovu — could be tainted by safety concerns.
On Sunday night, Chicago-based American Society of Retina Specialists (ASRS) issued a note to members about 14 cases of retinal vasculitis (including 11 cases of occlusive retinal vasculitis) — a sight-threatening inflammatory eye condition that involves the retinal vessels — across 46,000 injections administered since Beovu’s launch in November 2019, Wall Street analysts reported.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.